Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer
摘要:
Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance. Secondary mut
展开
关键词:
Animals Humans Carcinoma, Non-Small-Cell Lung Lung Neoplasms Quinazolines Receptor, Epidermal Growth Factor Intercellular Signaling Peptides and Proteins Proto-Oncogene Proteins Protein Kinase Inhibitors Xenograft Model Antitumor Assays
DOI:
10.1038/ng.2330
被引量:
年份:
2012






























































通过文献互助平台发起求助,成功后即可免费获取论文全文。
相似文献
参考文献
引证文献
辅助模式
引用
文献可以批量引用啦~
欢迎点我试用!